DNA methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer.
DNA methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer.
复制标题
DOI：
10.1111/j.1753-4887.2008.00061.x
复制
发表时间：
2008-08
影响因子：
6.1
通讯作者：
Stidley CA
中科院分区：
文献类型：
--
作者：
Belinsky SA;Schiller JH;Stidley CA
生物体液中的基因启动子甲基化正在成为一种重要的生物标志物，对肺癌的早期发现和监测、预防和干预具有重要意义。对具有不同肺癌风险的女性的痰和血浆中多基因启动子甲基化的发生率进行了评估。参与硒化学预防试验的肺癌幸存者显示，与无癌吸烟者和从不吸烟者相比，痰和血浆中甲基化的患病率最高。痰对肿瘤活检组织中基因甲基化状态的分类具有优势，四种基因联合作用的阳性预测值为86%。肺癌是美国与癌症相关的死亡的主要原因，不久将在全球范围内达到流行水平。通过及早发现和确定哪些高危个人可以受益于能够逆转或阻碍癌前疾病进展的化学预防战略，可以降低这种疾病的死亡率。因此，开发能够预测有前景的化学预防药物疗效的生物标志物是非常必要的。1996年，拉里·克拉克博士报告了一项使用L-硒蛋氨酸化学预防皮肤癌的研究。1尽管皮肤癌预防的主要终点为阴性，但在服用硒的组中，预期肺癌的发生率下降了约50%。这一发现导致了ECOG 5597的实施，即“在切除的I期非小细胞肺癌患者中补充硒的第三阶段化学预防试验。”这项试验正在验证这样一个假设，即给予200微克L-硒蛋氨酸作为硒酵母，可以降低Ia(T1N0)或Ib(T2N0)非小细胞肺癌根治性手术患者的第二原发癌发生率。
Gene promoter methylation in biological fluids is emerging as a biomarker that could be important for early detection of lung cancer and monitoring prevention and intervention. The prevalence of methylation of multiple gene promoters was evaluated in sputum and plasma from women at different risk for lung cancer. Lung cancer survivors participating in the selenium chemoprevention trial showed the highest prevalence for methylation in sputum and plasma compared to cancer-free smokers and never smokers. Sputum was superior for classifying methylation status of genes in tumor biopsies with a positive predictive value of 86% for the combined effect of four genes.Lung cancer is the leading cause of cancer-related death in the United States and will soon reach epidemic levels worldwide. Mortality from this disease could be reduced through early detection and the identification of high-risk individuals who could benefit from chemopreventive strategies that can reverse or impede the progression of premalignant disease. Therefore, it is essential to develop biomarkers that can predict the efficacy of promising chemopreventive agents. In 1996, Dr. Larry Clark reported a study on skin cancer chemoprevention using L-selenomethionine. 1 Although the primary endpoint of skin cancer prevention was negative, the rate of expected lung cancer in the group taking selenium decreased by approximately 50%. This finding led to the implementation of ECOG 5597,“A Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer.” This trial is testing the hypothesis that 200 µg of L-selenomethionine given as selenized yeast can decrease the rate of second primary tumors in patients who have undergone curative surgery for stages Ia (T1N0) or Ib (T2N0) non-small cell lung cancer.
登录
查看更多内容
影响因子：
11.5
作者：
Belinsky, SA;Klinge, DM;Picchi, MA
通讯作者：
Picchi, MA
影响因子：
11.2
作者：
Yang, Allen S.;Doshi, Ketan D.;Issa, Jean-Pierre J.
通讯作者：
Issa, Jean-Pierre J.
DOI：
10.1073/pnas.95.20.11891
发表时间：
1998-09-29
影响因子：
11.1
作者：
Belinsky, SA;Nikula, KJ;Herman, JG
通讯作者：
Herman, JG
影响因子：
8.8
作者：
Belinsky, S. A.;Grimes, M. J.;Casas, E.;Stidley, C. A.;Franklin, W. A.;Bocklage, T. J.;Johnson, D. H.;Schiller, J. H.
通讯作者：
Schiller, J. H.
影响因子：
11.2
作者：
Belinsky, SA;Liechty, KC;Byers, T
通讯作者：
Byers, T